Jason Gotlib

Dr. Jason Gotlib is Professor of Medicine in the Division of Hematology at the Stanford University School of Medicine / Stanford Cancer Institute. His medical school, internal medicine, and hematology/oncology fellowship training were undertaken at Stanford, where he also earned a master’s degree in clinical epidemiology.

His research focus is clinical and translational evaluation of novel therapies for myeloproliferative neoplasms, with a focus on KIT inhibitors for systemic mastocytosis (SM). Dr. Gotlib has authored more than 250 research articles, chapters, and reviews that have been published in journals including Blood, Journal of Clinical Oncology, Nature Medicine, and The New England Journal of Medicine. He is Vice-Chair of the NCCN Guidelines Committee on Myeloproliferative Neoplasms, and chaired the NCCN guideline development for SM. He led the clinical development of midostaurin and avapritinib for patients with advanced SM, as well as response criteria for these diseases which are used by regulatory agencies for drug approval. Dr. Gotlib was awarded the European Competence Network on Mastocytosis (ECNM) Medal as Researcher of the Year in 2019 for the development of KIT-targeting therapies in advanced SM.

Dr. Gotlib currently serves as President of the American Initiative in Mast Cell Diseases (AIM). He is actively involved with the American Society of Hematology where he has served as Editor-in-Chief of ASH’s The Hematologist, was Educational Co-Chair for the 2019 annual meeting and currently serves as Associate Editor for Blood. Dr. Gotlib enjoys landscape photography in his spare time.

Gail J. Roboz, MD is Professor of medicine and director of the clinical and translational leukemia programs at Weill Cornell Medicine and the New York Presbyterian Hospital in New York. New York, USA.

Dr. Roboz graduated summa cum laude from Yale University and Alpha Omega Alpha from the Mount Sinai School of Medicine, where she also achieved the highest academic standing in the graduating class. Dr. Roboz completed internship in Internal Medicine at the Beth Israel Hospital in Boston and residency at The New York Presbyterian Hospital. She completed fellowship in hematology and medical oncology at Weill Cornell Medical College and The New York Presbyterian Hospital.

Dr. Roboz’s research interests are in developmental therapeutics and novel clinical trial design for acute leukemias, myelodysplastic syndrome, and myeloproliferative disorders. She is the principal investigator on numerous investigator-initiated, cooperative group, and industry-sponsored clinical trials in these areas and has authored many related manuscripts and abstracts. Dr. Roboz serves on the Leukemia Core Committee for the Alliance clinical trials in oncology and is the Weill Cornell Principal Investigator for the MDS Clinical Research Consortium. She chairs the clinical committee of the European Leukemia Net (ELN) working group on measurable residual disease in acute myeloid leukemia. She also serves on the Scientific Advisory Board of the Aplastic Anemia and MDS International Foundation. Dr. Roboz has played an active role as a chair, speaker and panelist at numerous national and international conferences and is the recipient of prestigious honors and awards in the field.

Dr. Jason Gotlib is Professor of Medicine in the Division of Hematology at the Stanford University School of Medicine / Stanford Cancer Institute. His medical school, internal medicine, and hematology/oncology fellowship training were undertaken at Stanford, where he also earned a master’s degree in clinical epidemiology.

His research focus is clinical and translational evaluation of novel therapies for myeloproliferative neoplasms, with a focus on KIT inhibitors for systemic mastocytosis (SM). Dr. Gotlib has authored more than 250 research articles, chapters, and reviews that have been published in journals including Blood, Journal of Clinical Oncology, Nature Medicine, and The New England Journal of Medicine. He is Vice-Chair of the NCCN Guidelines Committee on Myeloproliferative Neoplasms, and chaired the NCCN guideline development for SM. He led the clinical development of midostaurin and avapritinib for patients with advanced SM, as well as response criteria for these diseases which are used by regulatory agencies for drug approval. Dr. Gotlib was awarded the European Competence Network on Mastocytosis (ECNM) Medal as Researcher of the Year in 2019 for the development of KIT-targeting therapies in advanced SM.

Dr. Gotlib currently serves as President of the American Initiative in Mast Cell Diseases (AIM). He is actively involved with the American Society of Hematology where he has served as Editor-in-Chief of ASH’s The Hematologist, was Educational Co-Chair for the 2019 annual meeting and currently serves as Associate Editor for Blood. Dr. Gotlib enjoys landscape photography in his spare time.

Dr. Kaner is the Director of the Inpatient Leukemia Service at Weill Cornell Medicine. He is also Director of the HLH Consult service and the HLH clinical and translational research program. He specializes in the diagnosis and management of inpatients with acute leukemias (ALL,AML, APL, MPAL, AUL), and other bone marrow disorders including aplastic anemia, MDS, CML, MPN and HLH. In addition, Dr. Kaner is the Associate Director of the Hematology and Medical Oncology Fellowship Program.

Dr. Kaner is a clinical investigator and focuses his clinical and research practice on improving outcomes for patients with various types of acute leukemia and hemophagocytic lymphohistiocytosis.

Maria Sirenko, PhD is a Postdoctoral Fellow at NYU Grossman School of Medicine (Perlmutter Cancer Center, Deptartment of Pathology), co-mentored by Drs. Iannis Aifantis and David Beck. She earned her PhD in Cancer Biology from the Gerstner Sloan Kettering Graduate School of Biomedical Sciences at Memorial Sloan Kettering Cancer Center in the lab of Dr. Elli Papaemmanuil. Her research focuses on the genomic and cellular drivers of myeloid malignancies, with particular emphasis on the intersection of inflammation and blood cancers. She has led large-scale studies to understand the overlap of myelodysplastic syndromes and VEXAS (Vacuoles, E1 enzyme, X-linked, Autoinflammatory, and Somatic) syndrome. She has also developed integrative single-cell frameworks to dissect genetic and cellular heterogeneity in acute myeloid leukemia and study responses to targeted inhibitors including IDH and venetoclax. Dr. Sirenko is a Cancer Research Institute Immuno-Informatics Fellow, EvansMDS Young Investigator, and ASH Scholar Fellow.

Gail J. Roboz, MD is Professor of medicine and director of the clinical and translational leukemia programs at Weill Cornell Medicine and the New York Presbyterian Hospital in New York. New York, USA.

Dr. Roboz graduated summa cum laude from Yale University and Alpha Omega Alpha from the Mount Sinai School of Medicine, where she also achieved the highest academic standing in the graduating class. Dr. Roboz completed internship in Internal Medicine at the Beth Israel Hospital in Boston and residency at The New York Presbyterian Hospital. She completed fellowship in hematology and medical oncology at Weill Cornell Medical College and The New York Presbyterian Hospital.

Dr. Roboz’s research interests are in developmental therapeutics and novel clinical trial design for acute leukemias, myelodysplastic syndrome, and myeloproliferative disorders. She is the principal investigator on numerous investigator-initiated, cooperative group, and industry-sponsored clinical trials in these areas and has authored many related manuscripts and abstracts. Dr. Roboz serves on the Leukemia Core Committee for the Alliance clinical trials in oncology and is the Weill Cornell Principal Investigator for the MDS Clinical Research Consortium. She chairs the clinical committee of the European Leukemia Net (ELN) working group on measurable residual disease in acute myeloid leukemia. She also serves on the Scientific Advisory Board of the Aplastic Anemia and MDS International Foundation. Dr. Roboz has played an active role as a chair, speaker and panelist at numerous national and international conferences and is the recipient of prestigious honors and awards in the field.

Dr. Jason Gotlib is Professor of Medicine in the Division of Hematology at the Stanford University School of Medicine / Stanford Cancer Institute. His medical school, internal medicine, and hematology/oncology fellowship training were undertaken at Stanford, where he also earned a master’s degree in clinical epidemiology.

His research focus is clinical and translational evaluation of novel therapies for myeloproliferative neoplasms, with a focus on KIT inhibitors for systemic mastocytosis (SM). Dr. Gotlib has authored more than 250 research articles, chapters, and reviews that have been published in journals including Blood, Journal of Clinical Oncology, Nature Medicine, and The New England Journal of Medicine. He is Vice-Chair of the NCCN Guidelines Committee on Myeloproliferative Neoplasms, and chaired the NCCN guideline development for SM. He led the clinical development of midostaurin and avapritinib for patients with advanced SM, as well as response criteria for these diseases which are used by regulatory agencies for drug approval. Dr. Gotlib was awarded the European Competence Network on Mastocytosis (ECNM) Medal as Researcher of the Year in 2019 for the development of KIT-targeting therapies in advanced SM.

Dr. Gotlib currently serves as President of the American Initiative in Mast Cell Diseases (AIM). He is actively involved with the American Society of Hematology where he has served as Editor-in-Chief of ASH’s The Hematologist, was Educational Co-Chair for the 2019 annual meeting and currently serves as Associate Editor for Blood. Dr. Gotlib enjoys landscape photography in his spare time.

Dr. Kaner is the Director of the Inpatient Leukemia Service at Weill Cornell Medicine. He is also Director of the HLH Consult service and the HLH clinical and translational research program. He specializes in the diagnosis and management of inpatients with acute leukemias (ALL,AML, APL, MPAL, AUL), and other bone marrow disorders including aplastic anemia, MDS, CML, MPN and HLH. In addition, Dr. Kaner is the Associate Director of the Hematology and Medical Oncology Fellowship Program.

Dr. Kaner is a clinical investigator and focuses his clinical and research practice on improving outcomes for patients with various types of acute leukemia and hemophagocytic lymphohistiocytosis.

Maria Sirenko, PhD is a Postdoctoral Fellow at NYU Grossman School of Medicine (Perlmutter Cancer Center, Deptartment of Pathology), co-mentored by Drs. Iannis Aifantis and David Beck. She earned her PhD in Cancer Biology from the Gerstner Sloan Kettering Graduate School of Biomedical Sciences at Memorial Sloan Kettering Cancer Center in the lab of Dr. Elli Papaemmanuil. Her research focuses on the genomic and cellular drivers of myeloid malignancies, with particular emphasis on the intersection of inflammation and blood cancers. She has led large-scale studies to understand the overlap of myelodysplastic syndromes and VEXAS (Vacuoles, E1 enzyme, X-linked, Autoinflammatory, and Somatic) syndrome. She has also developed integrative single-cell frameworks to dissect genetic and cellular heterogeneity in acute myeloid leukemia and study responses to targeted inhibitors including IDH and venetoclax. Dr. Sirenko is a Cancer Research Institute Immuno-Informatics Fellow, EvansMDS Young Investigator, and ASH Scholar Fellow.